Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered Long-acting Formulations of VH4011499 in Adults Without HIV

NCT06724640 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT06724640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06724640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled, Randomized, Single Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered Long-acting Formulations of VH4011499 in Adults Without HIV
Lead sponsor
ViiV Healthcare
Phase
Phase 1
Overall status
Recruiting
Start date
December 16, 2024
Completion date
August 16, 2028
Enrollment
168 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections